In ovarian cancer patients, the BRCA1 mutation has shown a 4-fold greater risk for brain metastases compared to the BRCA1 wildtype and has led to an 8-month earlier diagnosis of brain metastasis (Ratner et al., 2019). This evidence concerns the gene BRCA1 and ovarian carcinoma.